Drotaverinum of / хл TB. 0,04 No. 20

General characteristics. Structure:

Active ingredient: Drotaverinum.

Chemical: 1-[3,4 Diethoxy-phenyl) a methylene] -6,7-диэтокси-1,2,3,4-тетрагидроизохинолин (in the form of a hydrochloride).

Pharmacological properties:

Spasmolysant of myotropic action. On chemical structure and pharmacological properties it is close to a papaverine, however surpasses it in efficiency and duration of action. Reduces a tone of unstriated muscles of internals, reduces their physical activity. Has vazodilatiruyushchy effect.

Pharmacokinetics. After intake Drotaverinum is quickly absorbed from a GIT. Bioavailability - about 100%. Does not get through GEB.

Indications to use:

Prevention and treatment of the functional disturbances and pain syndrome caused by a spasm of smooth muscles (including the spasms of a GIT, urinary tract connected with a cholelithiasis, cholecystitis, a peptic ulcer of a stomach, duodenum; spasm of peloric and cardial department of a stomach; spastic locks, spastic colitis; proctitis, tenesmus; postoperative gripes owing to a delay of gases; in connection with a nephrolithiasis, a pyelitis); when carrying out tool researches; spasms of peripheral arteries, brain vessels; альгодисменорея. For decrease in excitability of a uterus at pregnancy; at a uterus pharynx spasm in labor, long disclosure of a pharynx, puerperal pains, the menacing abortion.

Route of administration and doses:

Inside, in oil, in/in or п / to adults - on 40-80 mg of 1-3 times/days. At hepatic and renal gripes it is recommended to enter in/in slowly in a dose of 40-80 mg. At spasms of peripheral arteries Drotaverinum can be entered in / and. For children under 6 years at intake the single dose makes 10-20 mg, 6-12 years - 20 mg, the frequency of use of 1-2 times/days.

Features of use:

With care apply at patients with the expressed atherosclerosis of coronary arteries. Drotaverinum can be used as a part of a combination therapy for stopping of hypertensive crisis.

Side effects:

From cardiovascular system: heartbeat, feeling of heat; at in introduction cases of decrease in the ABP (are noted up to a collapse), development of AV blockade, emergence of arrhythmias. From respiratory system: at in introduction cases of oppression of a respiratory center are noted. Other: dizziness, sweating strengthening.

Interaction with other medicines:

At simultaneous use with tricyclic antidepressants, quinidine, procaineamide the decrease in the ABP caused by tricyclic antidepressants, quinidine and procaineamide amplifies. At simultaneous use spazmogenny activity of morphine decreases. At simultaneous use with a levodopa reduction of antiparkinsonichesky effect of a levodopa is possible. At simultaneous use action of a papaverine, Bendazolum and other spasmolysants amplifies (including m-holinoblokatorov). At simultaneous use with phenobarbital expressiveness of spasmolytic action of Drotaverinum increases.

Contraindications:

Hypersensitivity to Drotaverinum.

Issue conditions:

According to the recipe

Packaging:

Tablets on 0,04, in packaging of the 20th tablet.